Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca
This study has been completed.
Study NCT00128245   Information provided by Novartis
First Received: August 5, 2005   Last Updated: December 19, 2007   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Keratoconjunctivitis Sicca
Additional conditions recognized in this trial
Keratoconjunctivitis
Xerophthalmia
More general conditions related to this trial
Conjunctival Diseases
Conjunctivitis
Corneal Diseases
Dry Eye Syndromes
Eye Diseases
Keratitis
Lacrimal Apparatus Diseases
Interventions listed in this trial
Pimecrolimus
Additional drug interventions recognized in this trial
Tacrolimus
More general drug interventions related to this trial
Analgesics
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antirheumatic Agents
Central Nervous System Agents
Dermatologic Agents
Immunologic Factors
Immunosuppressive Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
Novartis


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services